Through the years, the Society has strived to meet the needs of both oncologists and patients. For oncology professionals, ESMO serves and offers support to its members in their daily practice and careers by sharing knowledge and expertise through scientific and educational activities. For patients, ESMO partners with cancer patient associations and groups, by promoting direct and pro-active involvement of patients in educational, political, and networking activities. For the benefit of both, professionals and patients, in 2006 ESMO became active at the political level in order to influence issues which could impact the oncology community.
About Micromet, Inc.
Micromet, Inc. (http://www.micromet-inc.com) is a biopharmaceutical company
developing novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. Four of its antibodies are currently
in clinical trials, while the remainder of the product pipeline is in
preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538)
is in a phase 2 clinical trial for the treatment of patients with acute
lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of
patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class
of antibodies that activate a patient's own cytotoxic T cells, considered
the most powerful "killer cells" of the human immune system, to eliminate
cancer cells. Micromet is developing blinatumomab in collaboration with
MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE
antibody in clinical trials, and is being developed by Micromet in a phase
1 clinical trial for the treatment of patients with lung or
gastrointestinal cancer. The third clinical stage antibody is adecatumumab,
also known as MT201, a human monoclonal antibody that tar
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved